Cara Therapeutics Inc.
TVRD
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approa…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$27M
▲ +38.0% YoY
Op. Margin
–
ROIC
-145.52%
▼ -34.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$27M
▼ -28.4% YoY
Net Debt
-$22M
Net Cash Position
Cash & Equiv.
$22M
5Y CAGR: -18.5%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with TVRD
Cara Therapeutics (TVRD) in three numbers
Questions about Cara Therapeutics
Is Cara Therapeutics (TVRD) overvalued?
Cara Therapeutics trades at 6.59 times earnings. Intrinsiqq's fair value calculator has no opening value for TVRD, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Cara Therapeutics a high-quality business?
Cara Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is net debt at -$22M, and its weakest is return on capital at -145.5%. The Quality tab shows every check against its target.
Does Cara Therapeutics (TVRD) pay a dividend?
No. Cara Therapeutics (TVRD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in TVRD's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TVRD
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.